Centenara Labs will be the new name taken replacing Rejuveron for the Swidish biotech company. In a strong performance earlier this year, Rejuveron Life Sciences AG secured $75 million double bond issue Series B with convertible loan financing. Centenara Labs is advancing toward endogenous stem cell regeneration with a small-molecule strategy. 

Its most advanced therapy, the early-stage EA-2353 program, is in Phase 1/Phase 2 combination studies for the potentially vision-threatening retinitis pigmentosa (RP) condition. Preliminary safety data just emerged from these trials, and “the indications here are encouraging,” one investigator said. 

The name change is a part of the more extensive rebranding program for developing additional differentiation of the company in the market, besides boosting its visibility. “Our passage to Centenara is an ambitious, strategic step which reflects our hard work with developing therapies for regenerative medicine and age-related disorders,” noted CEO Aksana Labokha. “Our new visual identity highlights our evolution and makes us stand out in the sphere of biotechnology, focusing on extension of quality life.” 

For RP, several other companies including Beacon Therapeutics and Nanoscope Therapeutics are in clinical trials using gene therapy approaches that have shown promising early results. 

Of course, hype can be both a blessing and a curse. The sector may have seen as much hype as bad news. While Unity Biotechnology, for example, abandoned its leading knee-pain program in 2020 after the drug failed a key midstage trial, AgeX Therapeutics had to endure some pretty difficult times until the biotech company found new life from a merger with Serina Therapeutics last year. 

Read More: Click Here